三阴乳腺癌内科治疗进展-肿瘤学专业论文.docxVIP

三阴乳腺癌的内科治疗进展 中文摘要 三阴乳腺癌( triple negative breast cancer，TNBC) 是雌激素受体 ( estrogen receptor，ER) 孕激素受体( progesterone receptor，PR) 和人表皮生长因子受体－ 2( human epidermal growth factor receptor 2，Her－2) 均表达缺失的乳腺癌，其具 有自己独特的病理和分子生物学特性，与乳腺癌基因1( breast cancer 1, BRCA1) 具有一定的相关性，与基底细胞样乳腺癌（ basal-like breast cancer, BLBC）有较 高的一致性。TNBC具有侵袭能力强、早期易复发、易远处转移，生存期短和预 后较其他类型乳腺癌差等临床特点。由于TNBC的激素受体和Her-2受体均阴性， 无内分泌治疗和抗Her-2受体靶向治疗的指征，联合化疗是其内科治疗的主要手 段，目前还没有标准的治疗方案。临床上主要以蒽环类或紫杉类为基础的联合化 疗为主，此类型乳腺癌对新辅助化疗较敏感，常规化疗疗效不佳。近年来对TNBC 的血管靶向药物的研究得到临床普遍关注，抗EGFR、VEGF及PARP抑制剂等靶 向药物逐渐应用于临床，探索新的靶向治疗通路及研发新的靶向治疗药物将有助 于人们采取有效的治疗方法来提高其疗效。 【关键词】 乳腺癌；三阴性；靶向治疗 Advances in medical treatment of triple-negative breast cancerAbstract Abstract Triple negative breast cancer ( TNBC) is a subgroup of breast cancers，defined by a lack of the expressions of estrogen，progesterone and HER-2 receptors，with its exclusive pathological and molecular biological characteristics ,which has some relevance with breast cancer gene 1 (breast cancer, BRCA1) and a close relationship with basal － like breast cancer ． TNBC have strong invasive ability of early recurrence, easy to distant metastasis, and short survival and poorer prognosis than other types of breast cancer. Since endocrine and HER2-targered therapy can not be applied, combination chemotherapy is the major mean of therapy. There is no standard treatment options at present. Anthracycline or taxane-based combination chemotherapy is the main treatment on clinical. This type of breast cancer is insensitive to neoadjuvant chemotherapy ， the effect of conventional chemotherapy curative is poor, vascular targeting drugs to clinical about TNBC are widespread concerned in recent years. Researches about the targeted therapy, which aimed at targets such as anti-EGFR, VEGF EGFR,and PARP inhibitors drugs and so on are gradually used in clinical. Explore new targeted therapy pathways and develop new targeted therapies may lead to improved therapies and better clinical outcomes of the disease .This ar